{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=asciminib", "query": { "intervention": "asciminib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 29, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=asciminib&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T01:15:31.180Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05143840", "title": "Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloid Leukemia, Chronic Phase", "Adult CML", "Leukemia, Myeloid", "Leukemia,Myeloid, Chronic" ], "interventions": [ { "name": "Single Agent Asciminib", "type": "DRUG" }, { "name": "Low TKI", "type": "COMBINATION_PRODUCT" }, { "name": "Elective Free Treatment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT", "OTHER" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2022-04-22", "completion_date": "2032-02", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-06T01:15:31.180Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Augusta, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05143840" }, { "nct_id": "NCT02857868", "title": "A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatic Impairment" ], "interventions": [ { "name": "ABL001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 32, "start_date": "2016-05-03", "completion_date": "2017-07-20", "has_results": false, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-09-06T01:15:31.180Z", "location_count": 3, "location_summary": "Miami, Florida • Orlando, Florida • Minneapolis, Minnesota", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02857868" }, { "nct_id": "NCT03595917", "title": "ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia", "Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis", "Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL" ], "interventions": [ { "name": "ABL001", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marlise Luskin, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-07-24", "completion_date": "2027-11-01", "has_results": false, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-09-06T01:15:31.180Z", "location_count": 4, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Buffalo, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03595917" }, { "nct_id": "NCT06516029", "title": "Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Myeloid Leukemia, Chronic Phase" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2023-04-21", "completion_date": "2023-10-02", "has_results": false, "last_update_posted_date": "2024-07-23", "last_synced_at": "2026-09-06T01:15:31.180Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06516029" }, { "nct_id": "NCT04925479", "title": "Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myeloid Leukemia, Philadelphia Positive" ], "interventions": [ { "name": "Asciminib Pediatric formulation group", "type": "DRUG" }, { "name": "Asciminib Adult formulation group", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 34, "start_date": "2021-12-27", "completion_date": "2031-11-01", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-09-06T01:15:31.180Z", "location_count": 8, "location_summary": "Indianapolis, Indiana • Boston, Massachusetts • Jackson, Mississippi + 5 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "New York", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04925479" }, { "nct_id": "NCT04971226", "title": "A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive" ], "interventions": [ { "name": "Imatinib", "type": "DRUG" }, { "name": "Nilotinib", "type": "DRUG" }, { "name": "Bosutinib", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Asciminib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 405, "start_date": "2021-10-06", "completion_date": "2031-01-18", "has_results": true, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-09-06T01:15:31.180Z", "location_count": 13, "location_summary": "Denver, Colorado • Fort Myers, Florida • Tallahassee, Florida + 9 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04971226" }, { "nct_id": "NCT04666259", "title": "Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Myelogenous Leukemia - Chronic Phase" ], "interventions": [ { "name": "ABL001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 56, "start_date": "2021-05-25", "completion_date": "2024-06-26", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-09-06T01:15:31.180Z", "location_count": 26, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Long Beach, California + 21 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04666259" }, { "nct_id": "NCT06148493", "title": "Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Myeloid Leukemia" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 425, "start_date": "2022-09-20", "completion_date": "2022-12-15", "has_results": false, "last_update_posted_date": "2023-11-28", "last_synced_at": "2026-09-06T01:15:31.180Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06148493" }, { "nct_id": "NCT07091019", "title": "A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Myelogenous Leukemia - Chronic Phase" ], "interventions": [ { "name": "TKIs", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 1000, "start_date": "2025-12-17", "completion_date": "2033-04-20", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-09-06T01:15:31.180Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Stockton, California • Torrance, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Stockton", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07091019" }, { "nct_id": "NCT04838041", "title": "Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Phase Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "Asciminib 40 MG", "type": "DRUG" }, { "name": "Asciminib 40 MG Twice Daily", "type": "DRUG" }, { "name": "Asciminib 80 MG daily", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Nilotinib", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2021-11-11", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-06T01:15:31.180Z", "location_count": 5, "location_summary": "Detroit, Michigan • Buffalo, New York • New York, New York + 2 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04838041" } ] }